{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:24:42Z","timestamp":1794255882136,"version":"4.9.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:00:00Z","timestamp":1784332800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:00:00Z","timestamp":1784332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s12325-026-03631-2","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T06:50:11Z","timestamp":1784357411000},"page":"5051-5081","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Expert Consensus on the Clinical Application of Sulodexide in Vascular Diseases"],"prefix":"10.1007","volume":"43","author":[{"given":"Yongjun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Consensus Working Group of the Vascular Surgery Branch of the China International Exchange and Promotive Association for Medical and Health Care, the Geriatric Pharmacy Professional Committee of the China Medical Education Association, and the Vascular Limb Salvage Branch of the Beijing Association of Holistic Integrative Medicine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,18]]},"reference":[{"key":"3631_CR1","unstructured":"MIMS. Sulodexide Product Profile Singapore: MIMS; 2025 [Available from: https:\/\/www.mims.com\/singapore\/drug\/info\/sulodexide\/patientmedicine\/sulodexide-oral"},{"issue":"1","key":"3631_CR2","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s13239-020-00485-9","volume":"12","author":"S Weinbaum","year":"2021","unstructured":"Weinbaum S, Cancel LM, Fu BM, Tarbell JM. The glycocalyx and its role in vascular physiology and vascular related diseases. Cardiovasc Eng Technol. 2021;12(1):37\u201371.","journal-title":"Cardiovasc Eng Technol"},{"issue":"4","key":"3631_CR3","doi-asserted-by":"publisher","first-page":"R508","DOI":"10.1152\/ajpregu.00340.2020","volume":"320","author":"KH Moore","year":"2021","unstructured":"Moore KH, Murphy HA, George EM. The glycocalyx: a central regulator of vascular function. Am J Physiol Regul Integr Comp Physiol. 2021;320(4):R508\u201318.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"4","key":"3631_CR4","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.ajpath.2019.07.022","volume":"190","author":"G Wang","year":"2020","unstructured":"Wang G, Tiemeier GL, van den Berg BM, Rabelink TJ. Endothelial glycocalyx hyaluronan: regulation and role in prevention of diabetic complications. Am J Pathol. 2020;190(4):781\u201390.","journal-title":"Am J Pathol"},{"issue":"02","key":"3631_CR5","first-page":"146","volume":"36","author":"RZW Wang","year":"2024","unstructured":"Wang RZW, Luo F, Wang M, Qin J. The role of glycocalyx injury in the occurrence and development of related diseases. Mod Pract Med. 2024;36(02):146\u20139.","journal-title":"Mod Pract Med"},{"issue":"3","key":"3631_CR6","first-page":"243","volume":"33","author":"V Masola","year":"2014","unstructured":"Masola V, Zaza G, Onisto M, Lupo A, Gambaro G. Glycosaminoglycans, proteoglycans and sulodexide and the endothelium: biological roles and pharmacological effects. Int Angiol. 2014;33(3):243\u201354.","journal-title":"Int Angiol"},{"key":"3631_CR7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jclinepi.2023.05.010","volume":"159","author":"HJ Sch\u00fcnemann","year":"2023","unstructured":"Sch\u00fcnemann HJ, Brennan S, Akl EA, Hultcrantz M, Alonso-Coello P, Xia J, et al. The development methods of official GRADE articles and requirements for claiming the use of GRADE\u2013A statement by the GRADE guidance group. J Clin Epidemiol. 2023;159:79\u201384.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"3631_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/(SICI)1098-1128(199801)18:1<1::AID-MED1>3.0.CO;2-4","volume":"18","author":"J Harenberg","year":"1998","unstructured":"Harenberg J. Review of pharmacodynamics, pharmacokinetics, and therapeutic properites of sulodexide. Med Res Rev. 1998;18(1):1\u201320.","journal-title":"Med Res Rev"},{"key":"3631_CR9","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-biochem-032620-104745","author":"A Gomez Toledo","year":"2025","unstructured":"Gomez Toledo A, Golden GJ, Cummings RD, Malmstr\u00f6m J, Esko JD. Endothelial glycocalyx turnover in vascular health and disease: rethinking endothelial dysfunction. Annu Rev Biochem. 2025. https:\/\/doi.org\/10.1146\/annurev-biochem-032620-104745.","journal-title":"Annu Rev Biochem"},{"key":"3631_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e29101","author":"R Qu","year":"2024","unstructured":"Qu R, Du W, Li S, Li W, Wei G, Chen Z, et al. Destruction of vascular endothelial glycocalyx during formation of pre-metastatic niches. Heliyon. 2024. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e29101.","journal-title":"Heliyon"},{"issue":"5","key":"3631_CR11","doi-asserted-by":"publisher","first-page":"6166","DOI":"10.1096\/fj.201901920R","volume":"34","author":"SA Mensah","year":"2020","unstructured":"Mensah SA, Nersesyan AA, Harding IC, Lee CI, Tan X, Banerjee S, et al. Flow\u2010regulated endothelial glycocalyx determines metastatic cancer cell activity. FASEB J. 2020;34(5):6166\u201384.","journal-title":"FASEB J"},{"issue":"2","key":"3631_CR12","first-page":"284","volume":"41","author":"GXX Lu","year":"2025","unstructured":"Lu GXX, Liu K. Research status of relationship between glycocalyx degradation and endothelial cell dysfunction. Chin J Clin Pharmacol. 2025;41(2):284\u20139.","journal-title":"Chin J Clin Pharmacol"},{"issue":"12","key":"3631_CR13","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1007\/s00125-010-1910-x","volume":"53","author":"LN Broekhuizen","year":"2010","unstructured":"Broekhuizen LN, Lemkes BA, Mooij HL, Meuwese MC, Verberne H, Holleman F, et al. Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia. 2010;53(12):2646\u201355.","journal-title":"Diabetologia"},{"key":"3631_CR14","doi-asserted-by":"crossref","unstructured":"Coccheri S, Mannello F. Development and use of sulodexide in vascular diseases: implications for treatment. Drug design, development and therapy. 2014:49\u201365.","DOI":"10.2147\/DDDT.S6762"},{"key":"3631_CR15","doi-asserted-by":"crossref","unstructured":"Cerletti C, Rajtar G, Marchi E, de Gaetano G, editors. Interaction between glycosaminoglycans, platelets, and leukocytes. Seminars in thrombosis and hemostasis; 1994: Copyright\u00a9 1994 by Thieme Medical Publishers, Inc.","DOI":"10.1055\/s-2007-1001909"},{"issue":"1","key":"3631_CR16","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/BF02591420","volume":"22","author":"M Barbanti","year":"1992","unstructured":"Barbanti M, Guizzardi S, Calanni F, Marchi E, Babbini M. Antithrombotic and thrombolytic activity of sulodexide in rats. Int J Clin Lab Res. 1992;22(1):179\u201384.","journal-title":"Int J Clin Lab Res"},{"issue":"6","key":"3631_CR17","doi-asserted-by":"publisher","first-page":"563","DOI":"10.23736\/S0392-9590.24.05339-2","volume":"43","author":"JA Diaz","year":"2024","unstructured":"Diaz JA, Gianesini S, Khalil RA. Glycocalyx disruption, endothelial dysfunction and vascular remodeling as underlying mechanisms and treatment targets of chronic venous disease. Int Angiol 2024;43:563\u201390. https:\/\/doi.org\/10.23736\/S0392-9590.24.05339-2","journal-title":"Int Angiol"},{"issue":"Supplement_1","key":"3631_CR18","doi-asserted-by":"publisher","DOI":"10.2337\/db20-566-P","volume":"69","author":"T Li","year":"2020","unstructured":"Li T, He X, Peng R, Fu X, Shi G, Chen Y. 566-P: Sulodexide suppresses NLRP3 inflammasome activation via NOX4\/ROS signaling in the retinal microvasculature. Diabetes. 2020;69(Supplement_1):566-P.","journal-title":"Diabetes"},{"issue":"1","key":"3631_CR19","first-page":"4989847","volume":"2017","author":"YN Liu","year":"2017","unstructured":"Liu YN, Zhou J, Li T, Wu J, Xie SH, Liu H-f, et al. Sulodexide protects renal tubular epithelial cells from oxidative stress-induced injury via upregulating klotho expression at an early stage of diabetic kidney disease. J Diabetes Res. 2017;2017(1):4989847.","journal-title":"J Diabetes Res"},{"issue":"1","key":"3631_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/jth.14324","volume":"17","author":"BJ Carroll","year":"2019","unstructured":"Carroll BJ, Piazza G, Goldhaber S. Sulodexide in venous disease. J Thromb Haemost. 2019;17(1):31\u20138.","journal-title":"J Thromb Haemost"},{"issue":"5","key":"3631_CR21","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1177\/030006059602400501","volume":"24","author":"A Gaddi","year":"1996","unstructured":"Gaddi A, Galetti C, Illuminati B, Nascetti S. Meta-analysis of some results of clinical trials on sulodexide therapy in peripheral occlusive arterial disease. J Int Med Res. 1996;24(5):389\u2013406.","journal-title":"J Int Med Res"},{"issue":"2","key":"3631_CR22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1185\/03007999309111537","volume":"13","author":"M Mauro","year":"1993","unstructured":"Mauro M, Palmieri G, Palazzini E, Barbanti M, Calanni Rindina F, Milani M. Pharmacodynamic effects of single and repeated doses of oral sulodexide in healthy volunteers. A placebo-controlled study with an enteric-coated formulation. Curr Med Res Opin. 1993;13(2):87\u201395.","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"3631_CR23","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/FJC.0000000000000778","volume":"75","author":"JD Raffetto","year":"2020","unstructured":"Raffetto JD, Yu W, Wang X, Calanni F, Mattana P, Ra K. Sulodexide improves contraction and decreases Matrix Metalloproteinase-2 and -9 in veins under prolonged stretch. J Cardiovasc Pharmacol. 2020;75(3):211\u201321.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"3","key":"3631_CR24","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.3390\/jcm12031019","volume":"12","author":"S Doganci","year":"2023","unstructured":"Doganci S, Ince ME, Demeli M, Ors Yildirim N, Pehlivanoglu B, Yildirim AK, et al. Sulodexide develops contraction in human saphenous vein via endothelium-dependent nitric oxide pathway. J Clin Med. 2023;12(3):1019.","journal-title":"J Clin Med"},{"issue":"3","key":"3631_CR25","doi-asserted-by":"publisher","first-page":"354","DOI":"10.2174\/1570161111311030010","volume":"11","author":"F Mannello","year":"1998","unstructured":"Mannello F, Medda V, Ligi D, Raffetto JD. Glycosaminoglycan sulodexide inhibition of MMP-9 gelatinase secretion and activity: possible pharmacological role against collagen degradation in vascular chronic diseases. Curr Vasc Pharmacol. 2013;11(3):354\u201365","journal-title":"Curr Vasc Pharmacol"},{"issue":"1","key":"3631_CR26","first-page":"47","volume":"24","author":"A Chupin","year":"2018","unstructured":"Chupin A, Katorkin S, Katel\u2019nitski\u012d I, Katel\u2019nitskaia O, Prostov I, Petrikov A, et al. Sulodexide in treatment of chronic venous insufficiency Results of the All-Russian multicenter programme ACVEDUCT. Angiol i sosudistaia khirurgiia Angiol Vascular Surg. 2018;24(1):47\u201355.","journal-title":"Angiol i sosudistaia khirurgiia Angiol Vascular Surg"},{"issue":"13","key":"3631_CR27","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1053\/euhj.2001.3033","volume":"23","author":"S Coccheri","year":"2002","unstructured":"Coccheri S, Scondotto G, Agnelli G, Palazzini E, Zamboni V. Sulodexide in the treatment of intermittent claudication. Results of a randomized, double-blind, multicentre, placebo-controlled study. Eur Heart J. 2002;23(13):1057\u201365.","journal-title":"Eur Heart J"},{"issue":"9","key":"3631_CR28","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1007\/s12325-016-0359-9","volume":"33","author":"N Elleuch","year":"2016","unstructured":"Elleuch N, Zidi H, Bellamine Z, Hamdane A, Guerchi M, Jellazi N. Sulodexide in patients with chronic venous disease of the lower limbs: clinical efficacy and impact on quality of life. Adv Ther. 2016;33(9):1536\u201349.","journal-title":"Adv Ther"},{"issue":"3","key":"3631_CR29","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s12325-020-01232-1","volume":"37","author":"AA Bignamini","year":"2020","unstructured":"Bignamini AA, Matu\u0161ka J. Sulodexide for the symptoms and signs of chronic venous disease: a systematic review and meta-analysis. Adv Ther. 2020;37(3):1013\u201333.","journal-title":"Adv Ther"},{"issue":"9","key":"3631_CR30","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1177\/02683555211015020","volume":"36","author":"G Pompilio","year":"2021","unstructured":"Pompilio G, Nicolaides A, Kakkos SK, Integlia D. Systematic literature review and network Meta-analysis of sulodexide and other drugs in chronic venous disease. Phlebology. 2021;36(9):695\u2013709.","journal-title":"Phlebology"},{"issue":"1","key":"3631_CR31","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1524-4725.1995.tb00107.x","volume":"21","author":"MP Goldman","year":"1995","unstructured":"Goldman MP, Sadick NS, Weiss RA. Cutaneous necrosis, telangiectatic matting, and hyperpigmentation following sclerotherapy etiology, prevention, and treatment. Dermatol Surg. 1995;21(1):19\u201329.","journal-title":"Dermatol Surg"},{"issue":"3","key":"3631_CR32","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1177\/0268355518779844","volume":"34","author":"CD Critello","year":"2019","unstructured":"Critello CD, Fiorillo AS, Cristiano MC, de Franciscis S, Serra R. Effects of sulodexide on stability of sclerosing foams. Phlebology. 2019;34(3):191\u2013200.","journal-title":"Phlebology"},{"issue":"1","key":"3631_CR33","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jvsv.2020.06.019","volume":"9","author":"AJG Ochoa","year":"2021","unstructured":"Ochoa AJG, Carrillo J, Manr\u00edquez D, Manrique F, Vazquez AN. Reducing hyperpigmentation after sclerotherapy: A randomized clinical trial. J Vasc Surg Venous Lymphat Disord. 2021;9(1):154\u201362.","journal-title":"J Vasc Surg Venous Lymphat Disord"},{"issue":"20","key":"3631_CR34","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1161\/CIRCULATIONAHA.115.016930","volume":"132","author":"GM Andreozzi","year":"2015","unstructured":"Andreozzi GM, Bignamini AA, Dav\u00ec G, Palareti G, Matu\u0161ka J, Hol\u00fd M, et al. Sulodexide for the prevention of recurrent venous thromboembolism: the sulodexide in secondary prevention of recurrent deep vein thrombosis (SURVET) study: a multicenter, randomized, double-blind, placebo-controlled trial. Circulation. 2015;132(20):1891\u20137.","journal-title":"Circulation"},{"key":"3631_CR35","doi-asserted-by":"publisher","first-page":"107602962110494","DOI":"10.1177\/10760296211049402","volume":"27","author":"G Palareti","year":"2021","unstructured":"Palareti G, Bignamini AA, Cini M, Li Y-J, Urbanek T, Madaric J, et al. Anticoagulation duration after first venous thromboembolism: real-life data from the international, observational WHITE study. Clin Appl Thromb Hemost. 2021;27:10760296211049402.","journal-title":"Clin Appl Thromb Hemost"},{"issue":"1","key":"3631_CR36","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11739-021-02765-1","volume":"17","author":"G Palareti","year":"2022","unstructured":"Palareti G, Bignamini A, Cini M, Li Y-J, Urbanek T, Madaric J, et al. Unprovoked or provoked venous thromboembolism: not the prevalent criterion to decide on anticoagulation extension in clinical practice of various countries\u2014the prospective, international, observational WHITE study. Intern Emerg Med. 2022;17(1):71\u201382.","journal-title":"Intern Emerg Med"},{"issue":"1","key":"3631_CR37","doi-asserted-by":"publisher","first-page":"37","DOI":"10.23736\/S0392-9590.22.04970-7","volume":"42","author":"G Palareti","year":"2023","unstructured":"Palareti G, Barinov V, Urbanek T, Cini M, Li YJ, Bouslama K, Matu\u0161ka J, Mansilha A, Madaric J, Sokurenko GY, Andreozzi GM; WHITE study group. Recurrences and bleeding during extended treatment of patients with venous thromboembolism: results of the international, prospective, observational WHITE study. Int Angiol. 2023;42(1):37\u201344.","journal-title":"Int Angiol"},{"key":"3631_CR38","volume-title":"Comparative analysis of the effects of drugs commonly used for secondary prevention following initial occurrence of venous thromboembolism","author":"L Jy","year":"2021","unstructured":"Jy L. Comparative analysis of the effects of drugs commonly used for secondary prevention following initial occurrence of venous thromboembolism. Suzhou, China: Soochow University; 2021."},{"issue":"2","key":"3631_CR39","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s11739-020-02381-5","volume":"16","author":"G Palareti","year":"2021","unstructured":"Palareti G, Legnani C, Antonucci E, Zorzi S, Bignamini AA, Lodigiani C, et al. Design and rationale of a randomized, placebo-controlled trial on the efficacy and safety of sulodexide for extended treatment in elderly patients after a first venous thromboembolism. Intern Emerg Med. 2021;16(2):359\u201368.","journal-title":"Intern Emerg Med"},{"key":"3631_CR40","unstructured":"Zou F, Jiang Q, Qu L. A meta-analysis of efficacy and safety of sulodexide in the prevention and treatment of venous thromboembolism. 2025. p. 1728\u201336."},{"issue":"1","key":"3631_CR41","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/CP9.0000000000000079","volume":"9","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Yang J, Chang G, Cong H, Dong Q, Fu W, et al. Chinese expert consensus on anti-thrombotic therapy for pan-vascular diseases (2024 edition). Cardiology Plus. 2024;9(1):49\u201369.","journal-title":"Cardiology Plus."},{"issue":"1","key":"3631_CR42","doi-asserted-by":"publisher","first-page":"61","DOI":"10.23736\/S0392-9590.25.05344-1","volume":"44","author":"PL Antignani","year":"2025","unstructured":"Antignani PL, Poredo\u0161 P, Gastaldi G, Spirkoska A, Mansilha A. Lower extremity arterial disease perspective: IUA consensus document on \u201cLEAD management\u201d. Part 2. Int Angiol. 2025;44(1):61\u201370 (PubMed PMID: 39932499. Epub 20250211. eng.).","journal-title":"Int Angiol"},{"key":"3631_CR43","unstructured":"Soiety CD. Chinese Society of Infectious Diseases, Chinese Society for Tissue Repair and Regeneration. Chinese guideline on prevention and management of diabetic foot (2019 edition)(II). Chin J Diabetes Mellitus. 2019;11(3)."},{"issue":"5","key":"3631_CR44","doi-asserted-by":"publisher","first-page":"382","DOI":"10.23736\/S0392-9590.23.05110-6","volume":"42","author":"PL Antignani","year":"2023","unstructured":"Antignani PL, Gargiulo M, Gastaldi G, Jawien A, Mansilha A, Poredos P. Lower extremity arterial disease perspective: IUA consensus document on \u201cLEAD management\u201d. Part 1. Int Angiol. 2023;42(5):382\u201395.","journal-title":"Int Angiol"},{"issue":"2","key":"3631_CR45","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1177\/1534734614534442","volume":"13","author":"A Piaggesi","year":"2014","unstructured":"Piaggesi A, Abbruzzese L, Mattaliano C, Bargellini I, Cicorelli A, Iacopi E, et al. Sulodexide as adjunctive therapy in diabetic foot patients with critical limb ischemia treated with percutaneous transluminal angioplasty. Int J Low Extrem Wounds. 2014;13(2):103\u20139.","journal-title":"Int J Low Extrem Wounds"},{"issue":"1","key":"3631_CR46","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0735-1097(94)90498-7","volume":"23","author":"M Condorelli","year":"1994","unstructured":"Condorelli M, Chiariello M, Dagianti A, Penco M, Dalla Volta S, Pengo V, et al. IPO-V2: a prospective, multicenter, randomized, comparative clinical investigation of the effects of sulodexide in preventing cardiovascular accidents in the first year after acute myocardial infarction. J Am Coll Cardiol. 1994;23(1):27\u201334.","journal-title":"J Am Coll Cardiol"},{"key":"3631_CR47","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1716874","author":"B Bikdeli","year":"2020","unstructured":"Bikdeli B, Chatterjee S, Kirtane AJ, Parikh SA, Andreozzi GM, Desai NR, et al. Sulodexide versus control and the risk of thrombotic and hemorrhagic events: Meta-analysis of randomized trials. Semin Thromb Hemost. 2020. https:\/\/doi.org\/10.1055\/s-0040-1716874. (Thieme Medical Publishers, Inc.).","journal-title":"Semin Thromb Hemost"},{"issue":"2","key":"3631_CR48","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S1056-8727(00)00134-3","volume":"15","author":"T Koblik","year":"2001","unstructured":"Koblik T, Sieradzki J, Sendur R, Biernat J, Czarnobilski K, Gryz E, et al. The effect of insulin and sulodexide (Vessel Due F) on diabetic foot syndrome: pilot study in elderly patients. J Diabetes Complications. 2001;15(2):69\u201374.","journal-title":"J Diabetes Complications"},{"issue":"6","key":"3631_CR49","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1097\/01.ASN.0000014254.87188.E5","volume":"13","author":"G Gambaro","year":"2002","unstructured":"Gambaro G, Kinalska I, Oksa A, Pontuch P, Hertlov\u00e1 M, Olsovsky J, et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di NAS randomized trial. J Am Soc of Nephrol. 2002;13(6):1615\u201325.","journal-title":"J Am Soc of Nephrol."},{"issue":"3","key":"3631_CR50","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1007\/s12325-021-01620-1","volume":"38","author":"AA Bignamini","year":"2021","unstructured":"Bignamini AA, Chebil A, Gambaro G, Matu\u0161ka J. Sulodexide for diabetic-induced disabilities: a systematic review and meta-analysis. Adv Ther. 2021;38(3):1483\u2013513.","journal-title":"Adv Ther"},{"issue":"6","key":"3631_CR51","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s00417-014-2746-8","volume":"253","author":"JH Song","year":"2015","unstructured":"Song JH, Chin HS, Kwon OW, Lim SJ, Kim HK, Group DR. Effect of sulodexide in patients with non-proliferative diabetic retinopathy: diabetic retinopathy sulodexide study (DRESS). Graefes Arch Clin Exp Ophthalmol. 2015;253(6):829\u201337.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"Suppl 1","key":"3631_CR52","first-page":"81","volume":"48","author":"F Rubbi","year":"2000","unstructured":"Rubbi F, Caramazza R, Boccia S, Cozza N, Ghinato U, Gulli R, et al. The effects of sulodexide on diabetic retinopathy. Minerva Cardioangiol. 2000;48(Suppl 1):81\u20132.","journal-title":"Minerva Cardioangiol"},{"key":"3631_CR53","unstructured":"Package leaflet of Sulodexide Soft Capsules (Vessel Due F\u00ae), (2021)."},{"key":"3631_CR54","unstructured":"Package leaflet of Sulodexide Injection (Vessel Due F\u00ae), (2021)."}],"updated-by":[{"DOI":"10.1007\/s12325-026-03777-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000}}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03631-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03631-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03631-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:03:22Z","timestamp":1794254602000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03631-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,18]]},"references-count":54,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["3631"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03631-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,18]]},"assertion":[{"value":"20 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised due to update in text","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12325-026-03777-z","URL":"https:\/\/doi.org\/10.1007\/s12325-026-03777-z","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"\u00a0Yongjun Li, Yu Zhao and Wei Ye have nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.\u00a0All members of the consensus group signed and provided consent for publication.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}